Staying at the Forefront of Innovation: How Industry Relationships Drive Clinical Excellence

by Michael Merrick.

At One Physics, staying on the cutting edge of medical physics isn’t just a talking point, it’s something we continually work to prove. While any physics team can claim to follow new trends, our physicists actively participate in early-stage collaboration with technology partners, including companies like IBA Dosimetry. These relationships are not merely affiliations, they give us meaningful input on how emerging tools are shaped and, more importantly, how they can be translated into real clinical benefit.

Advancing QA for SRS with myQA SRS
Stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) demand submillimeter precision. The myQA SRS system from IBA Dosimetry is a device many clinics may be aware of but haven’t yet fully leveraged. With a 0.4 mm resolution CMOS detector array and a 12 × 14 cm² active area, it offers the spatial fidelity of film combined with digital speed and convenience.

Its clinical relevance and accuracy was recently highlighted in a study presented at the 2025 Radiosurgery Society Annual Meeting by one of our current residents, who will be joining One Physics full-time. These are not abstract academic connections; they are the kind of practical, first-hand evaluations that make us confident in recommending new tools to the clinics we serve.

From Research to Routine Use
Some of our physicists were among the earliest to evaluate the clinical integration of myQA SRS. This early access allows us to identify limitations, develop streamlined workflows, and ensure safe, effective adoption. When clinics try to balance innovation with reliability, this type of testing and feedback loop becomes critical.

For instance, one of our residents is presenting a study at the 2025 AAPM Annual Meeting titled “Proactive Quality Assurance for Adaptive Radiotherapy: Real-Time MLC Verification with myQA SRS.” It explores how this system, originally designed for SRS, can be adapted for real-time MLC behavior monitoring during adaptive treatments, an emerging area with limited QA solutions today.

Looking ahead, we’re also investigating whether this system can independently validate key machine parameters such as MLC transmission and dosimetric leaf gap (DLG). Adding this type of verification into a clinic’s QA strategy provides added confidence and supports a more robust safety framework.

Empowering Resident Growth and Clinical Advancement
These vendor relationships also create value in less obvious but equally important ways. Residents and physicists gain early experience with next-generation tools and contribute to the available body of clinical research. This cultivates a stronger pipeline of well-rounded professionals who are ready to support evidence-based, progressive care environments.

Conclusion
We understand that adopting new technologies comes with risk and skepticism. But at One Physics, we actively reduce that risk by putting our physicists at the center of innovation, so that when we recommend a new approach, it’s grounded in clinical experience, not marketing. That mindset helps ensure we’re not just keeping up with the field, but leading it in ways that matter for patients, staff, and outcomes.